AngioDynamics is demonstrating remarkable market momentum, driven by impressive quarterly results, favorable analyst coverage, and a significant regulatory development concerning reimbursement rates.
Regulatory Milestone for Prostate Treatment
A pivotal development has emerged from US health authorities concerning AngioDynamics’ prostate ablation therapy. The new CPT-I code will remain within the APC-5362 category, maintaining a reimbursement rate of $10,860.07. This clarity, effective January 2026, is expected to streamline physician compensation and reduce claim denials from private insurers. Market experts at Canaccord Genuity anticipate that AngioDynamics will leverage this positive momentum throughout the entire 2026 fiscal year.
Quarterly Earnings Exceed Projections
The company’s financial performance for Q1 2026 provided a substantial boost. AngioDynamics reported net sales of $75.7 million, a 12.2 percent year-over-year increase that comfortably surpassed the $72.7 million forecast. Its Med-Tech segment was a particular standout, surging 26.1 percent to reach $35.3 million. Although the company posted a loss per share of -$0.10, this still beat the anticipated -$0.12, indicating better-than-expected financial management.
Should investors sell immediately? Or is it worth buying AngioDynamics?
Analyst Confidence and Price Targets
The strong quarterly data has solidified analyst optimism. Canaccord Genuity reaffirmed its “Buy” recommendation and lifted its price target from $17.00 to $18.00. Similarly, H.C. Wainwright maintained its “Buy” rating with a $16.00 price objective. The consensus price target among all covering analysts sits at $19.33, suggesting substantial upside potential from the current trading level.
Key stock metrics include:
* Current Share Price: $12.30
* 52-Week Low: $6.83
* 52-Week High: $13.50
* Year-to-Date Performance: +76%
With a powerful combination of solid fundamentals, rising institutional ownership, and supportive regulatory news, the equity’s upward trajectory appears well-supported. The 76 percent annual gain reflects a market that is increasingly confident in the company’s strategic direction.
Ad
AngioDynamics Stock: Buy or Sell?! New AngioDynamics Analysis from January 11 delivers the answer:
The latest AngioDynamics figures speak for themselves: Urgent action needed for AngioDynamics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 11.
AngioDynamics: Buy or sell? Read more here...
